[Cyclophosphamide in the treatment of immune hemocytopenias].
Personal experiences with the immunosuppressive therapy of immunohaemocytopenia by cyclophosphamide are represented. A significant therapeutic success in autoimmunohaemolytic anaemia could be registered in 22 patients treated from one to seven years. From a number of 11 patients 9 were in complete remission. In idiopathic thrombocytopenia, however, only 7 patients from a number of 10 were in a clinical remission, the number of thrombocytes remained unchanged. The control of the complement content and the component C'3 can be used well as an indicator for immunological defense when the activity of the process and the success of the therapy are to be evaluated.
D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D003176:Complement C3 / Q000032:analysis; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007165:Immunosuppression Therapy; D011241:Prednisone / Q000627:therapeutic use; D013156:Splenectomy; D013921:Thrombocytopenia / Q000188:drug therapy*
D003176:Complement C3; D003520:Cyclophosphamide; D011241:Prednisone
Zyklophosphamid in der Behandlung der Immunhämozytopenien